NY-ESO-1-specific T cell receptor-engineered T cells and Tranilast, a TRPV2 antagonist bivalent treatment enhances the killing of esophageal cancer: a dual-targeted cancer therapeutic route--广州生物医药与健康研究院2024

论文

论文题目

NY-ESO-1-specific T cell receptor-engineered T cells and Tranilast, a TRPV2 antagonist bivalent treatment enhances the killing of esophageal cancer: a dual-targeted cancer therapeutic route
作者

Obed Boadi Amissah,Wenfang Chen,Jean de Dieu Habimana,Yirong Sun,Lihui Lin,Yujie Liu,Ling Wang,Zhaoming Liu,Omar Mukama,Rajesh Basnet,Hohua Liu,Junyi Li,Xuanyan Ding,Lingshuang Lv,Min Chen,Yalin Liang,Rongqi Huang,Zhiyuan Li
论文出处
刊物名称

Cancer Cell International
年卷期页

2024, 24, 1, 64
联系作者

Obed Boadi Amissah,Rongqi Huang,Zhiyuan Li
影响因子

5.3
摘要
英文摘要
外单位作者单位
备注